White Paper
How Early-Stage Planning Strategies Are Optimizing Drug Development
Unlocking the Potential of Target Product Profiles (TPPs) in Modern R&D
Apr 03, 2025

In today's rapidly evolving pharmaceutical landscape, early-stage planning is crucial for optimizing drug development. This industry research report uncovers the importance of Target Product Profiles (TPPs) in guiding research and development, with 83% of biopharma companies recognizing their value. However, only 17% explore multiple TPPs for each asset, which may limit their ability to react to new data and changes in the competitive environment. This revealing report also highlights the challenges faced by budget holders and implementors, including regulatory compliance, indication selection, and securing resources. Advanced technologies like AI are seen as top future accelerators for early-stage drug development. By leveraging external expertise and advanced technologies, companies can stay ahead in the competitive landscape and optimize their drug development strategies.

Download the full report now to explore how you can overcome these challenges and drive innovation in your drug development processes!

Related solutions

Contact Us